Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim PharmafiledCriticalBoehringer Ingelheim Pharma
Priority to ECSP045195priorityCriticalpatent/ECSP045195A/en
Publication of ECSP045195ApublicationCriticalpatent/ECSP045195A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Un comprimido farmacéutico de dos capas que comprende una primera capa formulada para la liberación inmediata del antagonista del receptor de la angiotensina II telmisartán desde una matriz para comprimido que se disuelve que contiene telmisartán en forma sustancialmente amorfa, y una segunda capa formulada para la liberación inmediata de un diurético como hidroclorotiazida desde una matriz para comprimido que se desintegra rápidamente. Se describe también un método para producir el comprimido de dos capas.A two-layer pharmaceutical tablet comprising a first layer formulated for immediate release of the telmisartan angiotensin II receptor antagonist from a matrix for dissolving tablet containing telmisartan in substantially amorphous form, and a second layer formulated for immediate release of a diuretic such as hydrochlorothiazide from a matrix for rapidly disintegrating tablet. A method for producing the two-layer tablet is also described.
ECSP0451952004-07-162004-07-16
A TWO-LAYER PHARMACEUTICAL COMPRESSED UNDERSTANDING TELMISARTAN AND A DIURÉTICO AND THE PREPARATION OF SUCH COMPRESSED
ECSP045195A
(en)
Solid oral pharmaceutical dosage form comprising at its core nifedipine or nisoldipine and in a mantle coating around the core at least one angiotensin II antagonist and / or at least one diuretic; procedure for its preparation, useful to treat hypertension.
Pharmaceutical composition comprising: a nucleus with phenylephrine in the form of immediate release and an erodible layer comprising phenylephrine and a sustained-release matrix; Useful to treat symptoms of cold, influenza, allergies or non-allergic rhinitis.
Nitrogen heterocyclic compounds, tachykinin receptor antagonists; pharmaceutical agent comprising the compound; and use in the prophylaxis or treatment of a lower urinary tract disease, a gastrointestinal disease, or a disease of the central nervous system.
ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES DIHYDRATED MAGNETIC PANTOPRAZOL, WHERE THE TABLET FORM IS COMPOSED BY A NUCLEUS, A MIDDLE COAT AND AN OUTER LAYER; AND USE OF PHARMACEUTICAL COMPOSITION IN ULCERAS AND